- Home
- SNES vs PTIX Comparison
SNES vs PTIX Comparison
Compare SNES & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- PTIX
- Stock Information
- Founded
- SNES 2004
- PTIX 1994
- Country
- SNES United States
- PTIX United States
- Employees
- SNES N/A
- PTIX N/A
- Industry
- SNES Agricultural Chemicals
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- PTIX Health Care
- Exchange
- SNES Nasdaq
- PTIX Nasdaq
- Market Cap
- SNES 2.3M
- PTIX 2.0M
- IPO Year
- SNES 2016
- PTIX 2016
- Fundamental
- Price
- SNES $3.03
- PTIX $0.27
- Analyst Decision
- SNES Strong Buy
- PTIX
- Analyst Count
- SNES 1
- PTIX 0
- Target Price
- SNES $10.00
- PTIX N/A
- AVG Volume (30 Days)
- SNES 97.2K
- PTIX 599.7K
- Earning Date
- SNES 02-28-2025
- PTIX 03-31-2025
- Dividend Yield
- SNES N/A
- PTIX N/A
- EPS Growth
- SNES N/A
- PTIX N/A
- EPS
- SNES N/A
- PTIX N/A
- Revenue
- SNES $1,651,000.00
- PTIX N/A
- Revenue This Year
- SNES $76.36
- PTIX N/A
- Revenue Next Year
- SNES $103.47
- PTIX N/A
- P/E Ratio
- SNES N/A
- PTIX N/A
- Revenue Growth
- SNES 38.16
- PTIX N/A
- 52 Week Low
- SNES $1.90
- PTIX $0.25
- 52 Week High
- SNES $9.80
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- SNES 47.13
- PTIX 34.94
- Support Level
- SNES $3.18
- PTIX $0.25
- Resistance Level
- SNES $3.63
- PTIX $0.30
- Average True Range (ATR)
- SNES 0.42
- PTIX 0.03
- MACD
- SNES 0.00
- PTIX 0.00
- Stochastic Oscillator
- SNES 31.26
- PTIX 10.43
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.